Therapeutics News and Research

RSS

InVivo Therapeutics CEO to be honored as one of Irish Life Science 50

InVivo Therapeutics Corporation CEO Frank Reynolds will be honored by the Irish Voice and Irish America Magazine, in collaboration with the Irish Government, as one of the 'Irish Life Science 50.' The award is the first honor to be given to influential Irish Americans for their work in the field of life sciences and is aimed to recognize "diverse accomplishments and advancements in the industry," according the Irish Voice.

23 Apr 2010

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

The Fraunhofer Center for Molecular Biotechnology in Newark, Delaware, the Fraunhofer Center for Manufacturing Innovation in Boston, Massachusetts, the Boston University College of Engineering, and the biopharmaceutical company iBio, Inc. in Newark, Delaware, announced today that they have developed a fully automated, scalable "factory" that uses natural (non-genetically-modified) green plants to efficiently produce large quantities of vaccines and therapeutics within weeks.

23 Apr 2010

European Patent Office intends to grant patent for Intezyne's IVECT Method

Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne's breakthrough drug delivery technology, the IVECT Method. At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues.

23 Apr 2010

Researchers take major step to predict adverse drug reactions using genetic information

In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.

23 Apr 2010

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a poster at the American Association for Cancer Research's 101st Annual Meeting 2010 that details their novel study of molecules that use a tumor's acidic microenvironment to help them tailor chemotherapeutic agents to kill the tumor.

23 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.

23 Apr 2010

Nile Therapeutics prices underwritten public offering of common stock

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, announced the pricing of its previously announced underwritten public offering of 6,500,000 units of its securities at a public offering price of $0.70 per unit. Each unit consists of one share of Nile common stock and 0.30 warrants to purchase common stock.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

Aragon Pharmaceuticals raises $22M through Series B financing

Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.

23 Apr 2010

New gene therapy to restore retinal cone function and day vision

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

22 Apr 2010

MicroStockProfit.com announces investment report featuring Cell Therapeutics

MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

22 Apr 2010

Mild Cognitive Impairment Symposium is now 'Symposium on Early Alzheimer's Disease'

This year, the Miami Beach symposium kicked off on a rainy Friday with a new name and a new focus on biomarkers. For seven years, the meeting has been called the Mild Cognitive Impairment Symposium, but that changed this year to the Symposium on Early Alzheimer's Disease. The change comes as a nod to a recent and dramatic shift in how Alzheimer disease is perceived, and what researchers increasingly see as the most promising angle of attack for future therapeutics.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.

22 Apr 2010

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Celldex Therapeutics, Inc. today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, is the subject of a poster presentation at the 2010 American Association for Cancer Research 101st Annual Meeting in Washington DC.

22 Apr 2010

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Therapeutics News and Research

InVivo Therapeutics CEO to be honored as one of Irish Life Science 50

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

European Patent Office intends to grant patent for Intezyne's IVECT Method

Researchers take major step to predict adverse drug reactions using genetic information

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

Nile Therapeutics prices underwritten public offering of common stock

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Aragon Pharmaceuticals raises $22M through Series B financing

New gene therapy to restore retinal cone function and day vision

MicroStockProfit.com announces investment report featuring Cell Therapeutics

Mild Cognitive Impairment Symposium is now 'Symposium on Early Alzheimer's Disease'

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

ImmunoCellular Therapeutics, UPENN sign research agreement

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News